53 related articles for article (PubMed ID: 20151455)
21. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
22. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
[TBL] [Abstract][Full Text] [Related]
23. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth.
Takai N; Jain A; Kawamata N; Popoviciu LM; Said JW; Whittaker S; Miyakawa I; Agus DB; Koeffler HP
Cancer; 2005 Dec; 104(12):2701-8. PubMed ID: 16265675
[TBL] [Abstract][Full Text] [Related]
24. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression.
Nguyen A; Rosner A; Milovanovic T; Hope C; Planutis K; Saha B; Chaiwun B; Lin F; Imam SA; Marsh JL; Holcombe RF
Int J Oncol; 2005 Oct; 27(4):949-56. PubMed ID: 16142310
[TBL] [Abstract][Full Text] [Related]
25. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor changes during breast cancer metastasis.
Fuchs IB; Siemer I; Bühler H; Schmider A; Henrich W; Lichtenegger W; Schaller G; Kuemmel S
Anticancer Res; 2006; 26(6B):4397-401. PubMed ID: 17201160
[TBL] [Abstract][Full Text] [Related]
27. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
28. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
Liu B; Ordonez-Ercan D; Fan Z; Huang X; Edgerton SM; Yang X; Thor AD
Mol Cancer Res; 2009 Nov; 7(11):1882-92. PubMed ID: 19861407
[TBL] [Abstract][Full Text] [Related]
29. [Screening of a sub-clone of human breast cancer cells with high metastasis potential].
Ye LH; Wu LY; Guo W; Ma HT; Zhang XD
Zhonghua Yi Xue Za Zhi; 2006 Jan; 86(1):61-5. PubMed ID: 16606541
[TBL] [Abstract][Full Text] [Related]
30. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain.
Palmieri D; Bronder JL; Herring JM; Yoneda T; Weil RJ; Stark AM; Kurek R; Vega-Valle E; Feigenbaum L; Halverson D; Vortmeyer AO; Steinberg SM; Aldape K; Steeg PS
Cancer Res; 2007 May; 67(9):4190-8. PubMed ID: 17483330
[TBL] [Abstract][Full Text] [Related]
31. Options of flow cytometric three-colour DNA measurements to quantitate EGFR in subpopulations of human bladder cancer.
Brockhoff G; Endl E; Minuth W; Hofstädter F; Knüchel R
Anal Cell Pathol; 1996 Jun; 11(1):55-70. PubMed ID: 8844105
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal Cancer.
Kripp M; Merx K; Wirtz RM; Gaiser T; Eidt S; Schwaab J; Post S; Wenz F; Hochhaus A; Hofheinz RD; Erben P
Gastroenterol Res Pract; 2016; 2016():3481578. PubMed ID: 27610130
[TBL] [Abstract][Full Text] [Related]
33. Validation of a phosphoprotein array assay for characterization of human tyrosine kinase receptor downstream signaling in breast cancer.
Chergui F; Chrétien AS; Bouali S; Ramacci C; Rouyer M; Bastogne T; Genin P; Leroux A; Merlin JL
Clin Chem; 2009 Jul; 55(7):1327-36. PubMed ID: 19443568
[TBL] [Abstract][Full Text] [Related]
34. Quantum measurement enables single biomarker sensitivity in flow cytometry.
Sabines-Chesterking J; Burenkov IA; Polyakov SV
Sci Rep; 2024 Feb; 14(1):3891. PubMed ID: 38365797
[TBL] [Abstract][Full Text] [Related]
35. HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies.
Gandullo-Sánchez L; Capone E; Ocaña A; Iacobelli S; Sala G; Pandiella A
EMBO Mol Med; 2020 May; 12(5):e11498. PubMed ID: 32329582
[TBL] [Abstract][Full Text] [Related]
36. HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women.
Wege AK; Chittka D; Buchholz S; Klinkhammer-Schalke M; Diermeier-Daucher S; Zeman F; Ortmann O; Brockhoff G
Breast Cancer Res; 2018 Nov; 20(1):139. PubMed ID: 30458882
[TBL] [Abstract][Full Text] [Related]
37. The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers.
Lamarca A; Galdy S; Barriuso J; Moghadam S; Beckett E; Rogan J; Backen A; Billington C; McNamara MG; Hubner RA; Cramer A; Valle JW
PLoS One; 2018; 13(10):e0206007. PubMed ID: 30335866
[TBL] [Abstract][Full Text] [Related]
38. HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.
Portier BP; Minca EC; Wang Z; Lanigan C; Gruver AM; Downs-Kelly E; Budd GT; Tubbs RR
Oncotarget; 2013 Oct; 4(10):1662-72. PubMed ID: 24091566
[TBL] [Abstract][Full Text] [Related]
39. Multichromatic phenotyping of HER receptor coexpression in breast tumor tissue samples using flow cytometry--possibilities and limitations.
Vollmann-Zwerenz A; Diermeier-Daucher S; Wege AK; Sassen A; Schmidt-Brücken E; Hofstaedter F; Ortmann O; Nauwelaers F; Brockhoff G
Cytometry A; 2010 Apr; 77(4):387-98. PubMed ID: 20151455
[TBL] [Abstract][Full Text] [Related]
40. Expression of the HER family mRNA in breast cancer tissue and association with cell cycle inhibitors p21(waf1) and p27(kip1).
Kalemi TG; Papazisis KT; Lambropoulos AF; Voyatzi S; Kotsis A; Kortsaris AH
Anticancer Res; 2007; 27(2):913-20. PubMed ID: 17465220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
